Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda.
PWH
adherence measures
isoniazid preventive therapy
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
09
08
2022
accepted:
30
09
2022
entrez:
2
11
2022
pubmed:
3
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
Isoniazid (INH) preventative therapy is recommended for people with HIV (PWH) in resource-constrained settings. Valid measures are needed to assess adherence. We aimed to examine agreement between measures overall and by level of social desirability. PWH with latent tuberculosis (TB) were recruited in Mbarara, Uganda. Past 30-day adherence was measured by the number of days with pill bottle openings using a medication event monitoring system (MEMS) and self-reported number of days pills taken. INH concentration (INH plus acetyl INH and their ratio) in hair samples was measured. We used Bland-Altman plots to examine agreement between adherence measures and calculated the area under the receiver operating characteristics curve (AUROC) to determine if INH hair concentration predicted optimal MEMS-measured adherence (≥90%). A total of 301 participants enrolled; 92% were virologically suppressed, and adherence was high. The median (interquartile range [IQR]) number of pill bottle openings in 30 days was 28 (24-30) compared with 30 (28-30) via self-report. The median INH concentration (IQR) was 36.2 (17.2-62.4), and the INH:acetyl ratio was 2.43 (0.99-3.92). Agreement between self-reported and MEMS adherence was greater at more optimal adherence levels. INH:acetyl INH ratio was not predictive of optimal adherence according to MEMS (AUROC, 0.62; 95% CI, 0.52-0.72) in a subset (n = 161). Lower MEMS adherence levels compared with self-report suggest the need for objective adherence measures. Biologic measures have potential, although in this study INH concentration was not predictive of MEMS measured adherence. More data are needed to assess the accuracy of biologic measures.
Sections du résumé
Background
UNASSIGNED
Isoniazid (INH) preventative therapy is recommended for people with HIV (PWH) in resource-constrained settings. Valid measures are needed to assess adherence. We aimed to examine agreement between measures overall and by level of social desirability.
Methods
UNASSIGNED
PWH with latent tuberculosis (TB) were recruited in Mbarara, Uganda. Past 30-day adherence was measured by the number of days with pill bottle openings using a medication event monitoring system (MEMS) and self-reported number of days pills taken. INH concentration (INH plus acetyl INH and their ratio) in hair samples was measured. We used Bland-Altman plots to examine agreement between adherence measures and calculated the area under the receiver operating characteristics curve (AUROC) to determine if INH hair concentration predicted optimal MEMS-measured adherence (≥90%).
Results
UNASSIGNED
A total of 301 participants enrolled; 92% were virologically suppressed, and adherence was high. The median (interquartile range [IQR]) number of pill bottle openings in 30 days was 28 (24-30) compared with 30 (28-30) via self-report. The median INH concentration (IQR) was 36.2 (17.2-62.4), and the INH:acetyl ratio was 2.43 (0.99-3.92). Agreement between self-reported and MEMS adherence was greater at more optimal adherence levels. INH:acetyl INH ratio was not predictive of optimal adherence according to MEMS (AUROC, 0.62; 95% CI, 0.52-0.72) in a subset (n = 161).
Conclusions
UNASSIGNED
Lower MEMS adherence levels compared with self-report suggest the need for objective adherence measures. Biologic measures have potential, although in this study INH concentration was not predictive of MEMS measured adherence. More data are needed to assess the accuracy of biologic measures.
Identifiants
pubmed: 36320196
doi: 10.1093/ofid/ofac516
pii: ofac516
pmc: PMC9605696
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac516Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Clin Infect Dis. 2019 Mar 5;68(6):1044-1047
pubmed: 30184104
J Acquir Immune Defic Syndr. 2022 Aug 30;:
pubmed: 36044285
N Engl J Med. 2015 May 28;372(22):2127-35
pubmed: 26017823
PLoS One. 2016 May 18;11(5):e0155887
pubmed: 27191185
AIDS. 2009 Feb 20;23(4):471-8
pubmed: 19165084
Eur Respir J. 2017 Jul 13;50(1):
pubmed: 28705945
AIDS Patient Care STDS. 2008 Sep;22(9):735-43
pubmed: 18754705
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):311-5
pubmed: 24694932
Tuberc Res Treat. 2012;2012:327027
pubmed: 23091716
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Curr HIV/AIDS Rep. 2018 Feb;15(1):49-59
pubmed: 29380227
Alcohol Clin Exp Res. 2007 Jul;31(7):1208-17
pubmed: 17451397
Addiction. 2016 Feb;111(2):272-9
pubmed: 26381193
Int J Infect Dis. 2021 Dec;113 Suppl 1:S7-S12
pubmed: 33716195
Indian J Med Res. 2011 Mar;133:257-66
pubmed: 21441678
AIDS. 2015 Apr 24;29(7):825-30
pubmed: 25985404
Clin Infect Dis. 2011 May;52(10):1267-75
pubmed: 21507924
PLoS One. 2018 Jan 9;13(1):e0190118
pubmed: 29315307
AIDS Behav. 2014 Dec;18(12):2285-90
pubmed: 25280447
J Consult Psychol. 1960 Aug;24:349-54
pubmed: 13813058
AIDS Behav. 2020 Jun;24(6):1727-1742
pubmed: 31673913
AIDS Behav. 2006 May;10(3):227-45
pubmed: 16783535
Br J Clin Pharmacol. 2016 Jul;82(1):268-79
pubmed: 27005306
Med Pharm Rep. 2019 Apr;92(2):117-122
pubmed: 31086837
Transl Behav Med. 2015 Dec;5(4):470-82
pubmed: 26622919
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7
pubmed: 27155191
Curr HIV/AIDS Rep. 2020 Aug;17(4):301-314
pubmed: 32424549
Int J Tuberc Lung Dis. 2021 Jan 1;25(1):52-60
pubmed: 33384045